Keyphrases
Adrenocortical Carcinoma
100%
Molecular Regulation
100%
Ribonucleotide Reductase
100%
RRM2
100%
Ataxia Telangiectasia
60%
Ataxia Telangiectasia mutated
60%
Rad3
60%
RRM1
60%
DNA Damage Repair
40%
Repair Method
20%
Therapeutic Potential
20%
Cell Killing
20%
Chemotherapy
20%
Patient Care
20%
Cisplatin
20%
New Therapeutics
20%
Drug Resistance
20%
Treatment Options
20%
Gemcitabine
20%
Molecular Targets
20%
Checkpoint Kinase 1 (CHK1)
20%
Clinical Patients
20%
Systemic Treatment
20%
Mucin 1 (MUC1)
20%
WEE1
20%
Protein Signaling
20%
Repair System
20%
Drug Screening
20%
Adrenocortical Cell Line
20%
Targeted Inhibitors
20%
NCI-H295R
20%
Antitumoral
20%
Ribonucleotide Reductase Subunit M1
20%
Biochemistry, Genetics and Molecular Biology
Ribonucleotide Reductase
100%
RRM2
83%
Ataxia Telangiectasia Mutated
50%
RRM1
50%
DNA Repair
33%
Ataxia Telangiectasia and Rad3 Related
33%
P53
16%
Cisplatin
16%
Cell Killing
16%
Drug Resistance
16%
Signaling Protein
16%
Drug Screening
16%
Wee1
16%
Gemcitabine
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adrenal Cortex Carcinoma
100%
Ribonucleotide Reductase
100%
Ataxia Telangiectasia
83%
Protein P53
16%
Chemotherapy
16%
Drug Resistance
16%
Side Effect
16%
Cisplatin
16%
Gemcitabine
16%
Systemic Treatment
16%
Drug Screening
16%
ATR Protein
16%